Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Companyâ€™s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/11/26	$15.76	+0.64%	29,151
09/11/26	$15.66	-0.57%	25,931
06/11/26	$15.75	+0.38%	59,284
05/11/26	$15.69	-1.32%	21,864
04/11/26	$15.90	+0.25%	68,590

Delayed Quote Nasdaq

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Rallybio Corporation

Revisions to estimates

Quarterly earnings, Rate of surprise

Rate of surprise - EPS - Quarterly - Rallybio Corporation

Company calendar

Market Closed - Nasdaq 01:00:00 11/11/2026 +04			5-day change	1st Jan Change
15.76 ^USD	+0.64%		-0.63%	+187.13%

10-27	Rallybio Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
08-06	Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	84.85M 76.09M 70.13M 63.69M 121M 7.96B 124M 840M 335M 4.26B 318M 312M 13.47B	P/E 2026 *	-4.28x	P/E 2027 *	-4.38x
Enterprise Value	84.85M 76.09M 70.13M 63.69M 121M 7.96B 124M 840M 335M 4.26B 318M 312M 13.47B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	65.87%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	RLYB	Delayed
CBOE	RLYB	Real-time
Tradegate	33M0	Real-time
Deutsche Boerse AG	33M0	Delayed

10-27	Rallybio Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
08-06	Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Rallybio Corporation(NasdaqCM:RLYB) added to Russell Microcap Value Benchmark Index	CI
06-29	Rallybio Corporation(NasdaqCM:RLYB) added to Russell Microcap Index	CI
06-29	Rallybio Corporation(NasdaqCM:RLYB) added to Russell 3000E Value Benchmark	CI
06-29	Rallybio Corporation(NasdaqCM:RLYB) added to Russell 3000E Index	CI
06-02	Rallybio Corporation, Avenzo Therapeutics, Inc. - M&A Call
06-01	Rallybio Agrees to Acquire Avenzo Therapeutics	MT
06-01	Rallybio Corporation and Avenzo Therapeutics announce merger agreement to advance next-generation oncology therapies and $215 million concurrent private placement	RE
06-01	Avenzo Therapeutics, Inc. entered into a definitive agreement to acquire Rallybio Corporation in a reverse merger transaction.	CI
05-14	Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Rallybio Corp - Candid terminates merger agreement with Rallybio on May 3, 2026 - SEC filing	RE
05-03	Candid Therapeutics, Inc. cancelled the acquisition of Rallybio Corporation in a reverse merger transaction.	CI

Rallybio Corporation Stock

Stocks

RLYB

US75120L2097

Biotechnology & Medical Research

Valuation: Rallybio Corporation

Chart: Rallybio Corporation

Latest news: Rallybio Corporation

Last Transcript: Rallybio Corporation

Analysts' recommendations: Rallybio Corporation

Press Releases: Rallybio Corporation

News in other languages: Rallybio Corporation

Quotes and Performance

Price Extremes

Managers and Directors: Rallybio Corporation

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly earnings, Rate of surprise

14/04/25	Evercore ISI Downgrades Rallybio to In Line From Outperform	MT
09/04/25	HC Wainwright Downgrades Rallybio to Neutral From Buy	MT
15/05/24	JPMorgan Downgrades Rallybio to Neutral From Overweight	MT
11/04/24	Wedbush Lowers Rallybio's PT to $11 From $13 After Private Placement, Adjusts Full-Year 2024 Share Count; Maintains Outperform Rating	MT
13/03/24	HC Wainwright Cuts Rallybio Price Target to $9 From $12, Maintains Buy Rating	MT

11-11	Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo	BU
10-22	Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB	BU
06-02	Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB	BU
06-01	RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders	BU
06-01	Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement	BU

11/04/24	Aktien New York: Dow erholt sich vor Start in die Berichtssaison
11/04/24	Aktien New York: Dow schwächer vor Start in die Berichtssaison
11/04/24	Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet

1 day	+0.64%
1 week	-0.63%
Current month	+1.42%
1 month	-7.40%
3 months	-5.12%
6 months	+9.60%
Current year	+187.13%

1 week	15.28	16
1 month	15.28	17.08
Current year	3.67	17.57
1 year	3.67	17.57
3 years	1.76	27.68
5 years	1.76	141.08
10 years	1.76	206.24

Manager	Title	Age	Since
Stephen Uden CEO	Chief Executive Officer	68	01/08/2023
Jonathan Lieber DFI	Director of Finance/CFO	56	01/02/2023
Samantha Tracy IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Martin MacKay CHM	Chairman	69	01/01/2018
Stephen Uden BRD	Director/Board Member	68	01/08/2023
Helen Boudreau BRD	Director/Board Member	60	01/09/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
04/11/26	Ron Hunt	Exercice	Director	28,610	0.5314%
04/11/26	Martin MacKay	Exercice	Founder	66,448	1.2342%
02/11/26	Jonathan Lieber	Exercice	Chief Financial Officer	14,248	0.2646%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RALLYBIO CORPORATION	+0.64%	-0.63%	+203.12%	-31.36%	84.85M
WUXI APPTEC CO., LTD.	+0.01%	+11.10%	+60.83%	+70.43%	68.32B
ARGENX SE	+1.22%	+9.56%	+15.97%	+90.23%	60.26B
LONZA GROUP AG	+0.24%	+1.35%	+23.78%	+97.55%	55.86B
BEONE MEDICINES AG	+1.60%	+19.44%	+28.80%	+112.95%	48.43B
IQVIA HOLDINGS INC.	-1.32%	+4.78%	+29.15%	+40.40%	45.34B
REVOLUTION MEDICINES, INC.	-3.54%	-0.60%	+207.76%	+879.50%	41.76B
CELLTRION, INC.	-3.33%	+6.90%	+22.78%	+48.07%	34.5B
GENMAB A/S	-2.19%	-3.71%	+90.94%	+66.33%	33.8B
WUXI BIOLOGICS (CAYMAN) INC.	-1.61%	+0.99%	+46.81%	0.00%	25.96B
Average	-0.83%	+4.79%	+72.99%	+137.41%	41B
Weighted average by Cap.	-0.66%	+5.25%	+55.35%	+153.56%

	2026 *	2027 *
Net sales	-	-
Net income	-25.6M -22.96M -21.16M -19.22M -36.37M -2.4B -37.38M -253M -101M -1.29B -96.07M -94.04M -4.07B	-26.5M -23.77M -21.9M -19.89M -37.64M -2.48B -38.7M -262M -104M -1.33B -99.45M -97.34M -4.21B
Net Debt	-	-